Patents by Inventor Angus Gidley-Baird

Angus Gidley-Baird has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating cancer with a P2X7 peptide
    Patent number: 10597451
    Abstract: The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 24, 2020
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR
    Publication number: 20200071419
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Application
    Filed: September 11, 2019
    Publication date: March 5, 2020
    Applicant: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Combination therapy utilizing P2X7 peptides
    Patent number: 10543262
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimising the progression of cancer in said individuals.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: January 28, 2020
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor
    Patent number: 10450380
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: October 22, 2019
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Combination Therapy Utilizing P2X7 Peptides
    Publication number: 20190224290
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimising the progression of cancer in said individuals.
    Type: Application
    Filed: February 5, 2019
    Publication date: July 25, 2019
    Applicant: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Combination therapy utilizing P2X7 peptides
    Patent number: 10245308
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimizing the progression of cancer in said individuals.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: April 2, 2019
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Anti-P2Xpeptides and epitopes
    Patent number: 10238716
    Abstract: The invention relates to the identification of a novel epitope on non-function P2X7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor. Antibodies which bind to the epitope and peptides for generating the antibodies are described. The antibodies and peptides are useful in the diagnosis and treatment of cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 26, 2019
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Method for minimising progression of cancer in companion animals
    Patent number: 10232025
    Abstract: The invention relates to minimizing the progression of cancer in a companion animal using P2X7 immunotherapy.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 19, 2019
    Assignee: BIOSCEPTRE (AUSI) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • NOVEL P2X7 EPITOPES
    Publication number: 20180265580
    Abstract: The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer.
    Type: Application
    Filed: March 2, 2018
    Publication date: September 20, 2018
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Methods of treating cancer with antibodies that bind P2X7 receptors
    Patent number: 9944701
    Abstract: The invention relates to purinergic (P2X) receptors, to generation of antibodies and to use of antibodies and immunogens for detection and treatment of a disease or condition, especially cancer.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: April 17, 2018
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR
    Publication number: 20170327592
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 16, 2017
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • COMPANION ANIMAL TREATMENTS
    Publication number: 20170232085
    Abstract: The invention relates to minimising the progression of cancer in a companion animal using P2X7 immunotherapy.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 17, 2017
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Combination Therapy
    Publication number: 20170157229
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimising the progression of cancer in said individuals.
    Type: Application
    Filed: January 5, 2017
    Publication date: June 8, 2017
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Antibodies to non-functional P2X7 receptor
    Patent number: 9663584
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 30, 2017
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Combination therapy
    Patent number: 9566318
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimizing the progression of cancer in said individuals.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: February 14, 2017
    Assignee: Biosceptre (Aust) Pty Ltd
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Companion animal treatments
    Patent number: 9562094
    Abstract: The invention relates to minimizing the progression of cancer in a companion animal using P2X7 immunotherapy.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: February 7, 2017
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Antibodies to non-functional oligomeric P2X7 receptors and methods of use thereof
    Patent number: 9428587
    Abstract: The invention relates to purinergic receptors, to antibodies and related fragments thereof for binding to said receptors, to production of said antibodies and fragments and to sue of said antibodies and fragments for cancer detection and therapy. In particular the antibodies described bind specifically to non-functional P2X& receptors expressed by live cells.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: August 30, 2016
    Assignee: BIOSCEPTRE INTERNATIONAL LIMITED
    Inventors: Julian Alexander Barden, Angus Gidley-Baird, Glenn Ronald Pilkington
  • Anti- P2X7 Peptides and Epitopes
    Publication number: 20160199442
    Abstract: The invention relates to the identification of a novel epitope on non-function P2X7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor. Antibodies which bind to the epitope and peptides for generating the antibodies are described. The antibodies and peptides are useful in the diagnosis and treatment of cancer.
    Type: Application
    Filed: March 30, 2016
    Publication date: July 14, 2016
    Inventors: JULIAN ALEXANDER BARDEN, ANGUS GIDLEY-BAIRD
  • NOVEL P2X7 EPITOPES
    Publication number: 20160130342
    Abstract: The invention relates to purinergic (P2X) receptors, to generation of antibodies and to use of antibodies and immunogens for detection and treatment of a disease or condition, especially cancer.
    Type: Application
    Filed: October 7, 2015
    Publication date: May 12, 2016
    Applicant: BIOSCEPTRE INTERNATIONAL LIMITED
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Peptides for inducing antibodies to a non-functional P2Xreceptor
    Patent number: 9328155
    Abstract: The invention relates to a novel epitope on P2X7 receptors, to antibodies for binding to the epitope and to peptides for generating the antibodies.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: May 3, 2016
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird